Fast track — ArticlesEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
Introduction
People with diabetes mellitus are at high risk of cardiovascular disease. Epidemiological studies show that the risk of cardiovascular mortality is two to three times higher in men with diabetes and three to five times higher in women with diabetes than in people without diabetes.1, 2, 3, 4, 5, 6 The age-adjusted prevalence of coronary heart disease in white adults who have diabetes is about 45%, compared with about 25% in individuals without diabetes,7 and cardiovascular disease accounts for about 70% of all deaths in people with diabetes mellitus.8
The presence of other risk factors increases the risk of cardiovascular disease in people with diabetes mellitus. The absolute annual risk of fatal and non-fatal cardiovascular disease in middle-aged and elderly people with type 2 diabetes is 4-5%.1, 9, 10, 11, 12, 13 Despite decreases in the incidence of heart disease in the general population, the decline is much smaller in people with type 2 diabetes, and may even be rising in women with diabetes.13
Experimental studies, epidemiological studies, and clinical trials suggest that inhibitors of angiotensin-converting enzyme (ACE) may delay or prevent cardiovascular outcomes. For patients with diabetes, such benefit has been seen after acute myocardial infarction,14 in the presence of hypertension,15, 16, 17, 18, 19 and in the presence of a low ejection fraction or heart failure.20 ACE inhibitors may also prevent overt nephropathy and other microvascular outcomes in patients with type 1 or type 2 diabetes.17, 21, 22
Although studies suggest that ACE inhibitors may prevent or delay serious events in some subgroups, their role in a broader group of people with diabetes who are at high risk of cardiovascular events remains unknown. The Heart Outcomes Prevention Evaluation (HOPE) study investigated whether the addition of the ACE inhibitor ramipril to the current medical regimen of high-risk patients with diabetes mellitus can lower the risk of cardiovascular events. In the microalbuminuria, cardiovascular, and renal outcomes (MICRO) HOPE substudy, the effect of this intervention on the risk of overt nephropathy was investigated. We present here the results from these two studies for patients with diabetes mellitus.22
Section snippets
Participants
The HOPE and MICRO-HOPE study protocol has been published.23, 24 Briefly, people with and without diabetes were recruited, who were aged 55 years or older, and who had a history of cardiovascular disease (coronary artery disease, stroke, or peripheral vascular disease) or diabetes plus at least one other cardiovascular risk factor (total cholesterol > 5·2 mmol/L, HDL cholesterol ≪0·9 mmol/L, hypertension, known microalbuminuria, or current smoking). Key exclusion criteria were dipstick-positive
Results
Of all 9541 participants in the HOPE study, 3654 (39·3%) had diabetes at randomisation. 77 people who participated in another substudy in which they received only 2·5 mg ramipril or placebo were excluded from the analysis. Therefore, 3577 people with diabetes were included. The mean age was 65·4 years, 1322 (37%) were women, and 1996 (56%) had a history of hypertension. Baseline characteristics of participants in the ramipril and placebo groups were similar (table 1).
Of surviving participants
Discussion
Ramipril significantly lowered the risk of major cardiovascular outcomes by 25–30% in a broad range of high-risk middle-aged and elderly people with diabetes mellitus. The benefit was apparent irrespective of whether participants had a history of cardiovascular events, hypertension, or microalbuminuria, were taking insulin or oral antihyperglycaemic agents, or had type 1 or type 2 diabetes mellitus. The study had, however, low power to detect different effects in the subgroups. Since adherence
References (34)
- et al.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lancet
(1999) - et al.
Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry
Am J Cardiol
(1996) - et al.
Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus
Lancet
(1998) - et al.
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
Lancet
(1999) - et al.
Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients
Kidney Int
(1992) - et al.
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
Diabetes Care
(1993) - et al.
Diabetes and cardiovascular disease: the Framingham study
JAMA
(1979) - et al.
Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study
BMJ
(1983) - et al.
Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study
JAMA
(1991) - et al.
Factors predictive of long-term coronary heart disease mortality among 10059 male Israeli civil servants and municipal employees: a 23 year mortality follow-up in the Israeli Ischemic Heart Disease Study
Cardiology
(1993)
A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women
Arch Intern Med
Heart disease and diabetes
Hyperglycemia and cardiovascular disease in type 2 diabetes
Diabetes
Incidence of macrovascular disease in diabetes mellitus: the London follow-up to the WHO multinational study of vascular disease in diabetics
Diabetologia
Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment of diabetic retinopathy study report 14
JAMA
Eight to nine year mortality in known non-insulin dependent diabetes and controls
Kidney Int
A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM
Diabetes Care
Cited by (3342)
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week
2023, Journal of the American College of Cardiology2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)
2024, European Heart Journal: Acute Cardiovascular Care
Study organisation and investigators listed at end of paper